Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 30;40(2):322–333. doi: 10.1038/s41388-020-01530-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Immunoblot analyses of control (scram) and NRP1-depleted (shNRP1-01, shNRP1-02) D2.A1 cells. b Bioluminescent quantification of pulmonary tumor growth in animals injected via the lateral tail vein with control D2.A1 cells (scram) and those depleted for NRP1. Data are the mean ± SE of five mice per group at the indicated time points resulting in the indicated P value. c Bioluminescent quantification of pulmonary tumor growth following lateral tail vein injection with the D2.A1 cells. Animals were either treated with vehicle control (DMSO) or a covalent inhibitor of FGFR (FIIN4) at 100 mg/kg/Q.O.D. Data are the mean ± SE of five mice per group at the indicated time points resulting in the indicated P value. d Animals were injected and treated as described in b, c and upon necropsy, the average number of pulmonary tumor nodules per mouse were quantified for control, FIIN4-treated, and NRP1-depleted groups. e Representative H&E sections of single pulmonary lobes of control, FIIN4-treated and NRP1-depleted tumors. f Representative bioluminescent images for the indicated groups at the time of necropsy.